Korean J Hepatol > Volume 11(1); 2005 > Article
The Korean Journal of Hepatology 2005;11(1): 34-42.
HBV-specific CD8+ T cells for Sustained HBeAg Seroconversion after Lamivudine Therapy
Chun Kyon Lee, M.D., Kwang-Hyub Han, M.D.1,2, Jeong Hun Suh, M.D., Young Suk Cho, M.D., Sun Young Won, M.D., Chae Yoon Chon, M.D.1, Young Myoung Moon, M.D.1 and In Suh Park, M.D.
Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital, Koyang, Korea, Department of Internal Medicine, Yonsei University College of Medicine1, Brain Korea 21 Project for Medical Science2, Yonsei University, Seoul, Korea
ABSTRACT
Background/Aims
Viral suppression of the hepatitis B virus (HBV) can be induced by lamivudine, but the relapse seen in many patients after cessation of lamivudine therapy is troublesome. We thought that the host immune response is important to prevent viral relapse. We compared the frequency of HBV-specific CD8+ T cells in the peripheral blood and their expansion capacity after exposure to viral antigen between the patients showing sustained HBeAg seroconversion after use of lamivudine and those patients without sustained response. Methods: We analyzed HBV-specific CD8+ T cells that were isolated from the blood of 14 patients with HLA-A2 who showed lamivudine induced HBeAg seroconversion (HBV DNA < 0.5 pg/mL, and the cells were negative for HBeAg) at the end of lamivudine therapy. The purified T cells were directly stained ex vivo, after they had been stimulate with synthetic peptide, using the HBV core 18-27-specific HLA tetramer (Tc 18-27) and monoclonal antibody to CD8. The HBV viral load was quantified by the Amplicor HBV Monitor assay. Results: In patients with a sustained HBeAg response (the sustained group) for a duration of 15.5 months of follow-up, the median number of Tc 18-27 cells out of the 5×104 CD8+ T cells was 49.5 (15-135). On the contrary, in patients who experienced relapse (the relapsed group) during a median of 7.5 months of follow-up, the median number of Tc 18-27 cells out of the 5×104 CD8+ T cells was 13.5 (0-95). Especially, among patients with a viral load of HBV DNA < 1×103 copies at the end of treatment, the median number of Tc 18-27 cells out of 5×104 CD8+ T cells was 87 (45-135) in sustained group compared to 12 (6-50) in the relapsed group. All patients in the sustained group demonstrated a vigorous expansion of the core 18-27-specific CD8+ T cells after stimulation with viral peptide, in contrast to only 3 out of 8 patients in the relapsed group. Conclusions: This study demonstrates that the frequency and functional responsiveness of the circulating HBV-specific CD8+ T cells may be important for obtaining a sustained HBeAg response to lamivudine. (Korean J Hepatol 2005;11:34-42)
KeyWords: Lamivudine, HBV-specific CD8+ T cells, Sustained HBeAg response
TOOLS
METRICS Graph View
  • 2,112 View
  • 13 Download
Related articles

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1497
TOTAL : 1720696
Close layer